Matt Tindall, Martin Reese

Jun 22, 2017

Matt Tindall has stepped down as CEO of Fabric Genomics, formerly Omicia, as of early May 2017. He joined the company in March 2016 when he was first appointed to the position. Martin Reese, former CSO and co-founder, has been appointed as the company's CEO. Reese has served as CEO of the company in previous years.

Breaking News

FDA Grants Emergency Use Authorizations for Point-of-Care COVID Tests from Tangen Biosciences, SD Biosensor
Top Five Articles on GenomeWeb Last Week: FDA Proposal for LDT Oversight, Adela $48M Financing, More
FDA Grants Marketing Authorization for Invitae Hereditary Cancer DNA Sequencing Test
Compact Gene Editing Enzyme May Improve Success Rates of Gene Therapies
People in the News at Veracyte, Invitae, Mount Sinai, InterVenn Biosciences, Applied BioCode, More

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.